CD4 and neoplasm: In DT-treated DEREG mice challenged with tumor cells for 6 days, we observed a significant increase in the mean percentage of tumor-specific (tetramer II+) CD4+ T cells in comparison with mice that received only FBL-3 cells (Fig. 5a).